9bc1ce84-45e5-4c83-871c-02356d8311b9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.400
- PROTEIN_SECRETION+0.300
- TGF_BETA_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
- ANDROGEN_RESPONSE+0.200
- ANGIOGENESIS+0.200
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- COAGULATION+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V2-0.400
- MYC_TARGETS_V1-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ALLOGRAFT_REJECTION-0.200
- APICAL_SURFACE-0.200
- INFLAMMATORY_RESPONSE-0.200
- PANCREAS_BETA_CELLS-0.200
- GLYCOLYSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1BC-01A-11R-A12P-07 | — | A | 0.769 |
| 2 | C3N-02088 | — | cohortA1 | 0.740 |
| 3 | C3N-01021 | — | cohortA1 | 0.734 |
| 4 | BS_WFD0GE5X | EPN | Posterior Fossa EPN | 0.725 |
| 5 | TCGA-D8-A1XU-01A-11R-A14M-07 | — | A | 0.723 |
| 6 | BS_66ABA973 | pilocytic astrocytoma | — | 0.719 |
| 7 | 20020070.LumA | — | A | 0.710 |
| 8 | BS_4FZS7TX4 | EPN | EPN Tumor | 0.706 |
| 9 | SRR8613754 | — | F | 0.696 |
| 10 | C3L-02508 | — | cohortA1 | 0.692 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |